Page 198 - Drug Class Review
P. 198
Page 129 of 205
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Schneider et al.; 35 Potkin et al.; 74 Burns et al. 75 Year: 1998; 2002; 2004 Country: Multinational Novartis Pharmaceutical Study design: Meta-analysis Number of patients: 2,126 To assess the efficacy of RIV in patients with mild to moderately severe probable AD. Three RCTs (2 published Rosler 1998, Corey-Bloom 1998; 1 unpublished) NR Randomized, controlled, double-blinded trials with 26 weeks study durations. Unpublished trial was fixed dose (3mg, 6mg, 9mg); published trials partially flexible (1-4mg, 6-12mg) Patients with mild to moderately sever
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: DESIGN: AIMS OF REVIEW: STUDIES INCLUDED IN META-ANALYSIS TIME PERIOD COVERED: CHARACTERISTICS OF INCLUDED STUDIES: CHARACTERISTICS OF INCLUDED POPULATIONS: Alzheimer's Drugs
